表紙
市場調査レポート

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患) :パイプライン製品の分析

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 255954
出版日 ページ情報 英文 215 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患) :パイプライン製品の分析 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 215 Pages
概要

ロストリジウム・ディフィシルは消化管が感染するグラム陽性芽胞形成菌系の微生物です。入院患者や要介護者 (在宅/施設とも) などがしばしば、この微生物の毒素に感染し、消化器系疾患を引き起こしています。この疾患の症状には、下痢、大腸炎、中毒性巨大結腸、敗血症などが含まれていますが、これらは一括して「クロストリジウム・ディフィシル関連疾患」(CDAD)と呼ばれています。

当レポートでは、世界各国でのクロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患) 治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):企業で開発中の治療薬

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):大学/機関で研究中の治療薬

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):企業で開発中の製品

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):大学/機関で研究中の製品

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患) の治療薬開発に従事している企業

  • Absynth Biologics Limited
  • Actelion Ltd
  • Adenium Biotech ApS
  • AIMM Therapeutics B.V.
  • AmpliPhi Biosciences Corporation
  • Angothera GmbH
  • Appili Therapeutics
  • Assembly Biosciences, Inc.
  • AvidBiotics Corp.
  • C3 Jian, Inc
  • Da Volterra
  • 第一三共
  • e-Therapeutics Plc
  • Evec, Inc.
  • GangaGen Inc.
  • ImmunoBiology Limited
  • Immuron Limited
  • Inovio Pharmaceuticals, Inc.
  • Integrated BioTherapeutics, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • MGB Biopharma Limited
  • Microbiotix, Inc.
  • Micropharm Limited
  • Morphochem AG
  • Nanotherapeutics, Inc.
  • Novabiotics Limited
  • NovoBiotic Pharmaceuticals, LLC
  • Oragenics, Inc.
  • 大塚ホールディングス
  • Pfizer Inc.
  • Procarta Biosystems Limited
  • Prokarium Limited
  • Rebiotix Inc.
  • Sanofi Pasteur SA
  • Seres Therapeutics, Inc.
  • Shire Plc
  • Sorrento Therapeutics, Inc.
  • Stellar Biotechnologies, Inc.
  • Summit Therapeutics Plc
  • Synthetic Biologics, Inc.
  • Valevia UK Limited
  • Valneva SE
  • VaxInnate Corporation

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):最近のパイプライン動向

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):休止中のプロジェクト

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):開発が中止された製品

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7821IDB

Summary

Global Markets Direct's, 'Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2016', provides an overview of the Clostridium difficile Infections (Clostridium difficile Associated Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Clostridium difficile Associated Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Clostridium difficile Associated Disease)
  • The report reviews pipeline therapeutics for Clostridium difficile Infections (Clostridium difficile Associated Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Clostridium difficile Infections (Clostridium difficile Associated Disease) therapeutics and enlists all their major and minor projects
  • The report assesses Clostridium difficile Infections (Clostridium difficile Associated Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Clostridium difficile Associated Disease)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Clostridium difficile Infections (Clostridium difficile Associated Disease)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Clostridium difficile Infections (Clostridium difficile Associated Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) Overview
  • Therapeutics Development
    • Pipeline Products for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview
    • Pipeline Products for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Development by Companies
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Development by Companies
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Investigation by Universities/Institutes
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
    • Absynth Biologics Limited
    • Actelion Ltd
    • Adenium Biotech ApS
    • AIMM Therapeutics B.V.
    • AmpliPhi Biosciences Corporation
    • Angothera GmbH
    • Appili Therapeutics
    • Assembly Biosciences, Inc.
    • AvidBiotics Corp.
    • C3 Jian, Inc
    • Da Volterra
    • Daiichi Sankyo Company, Limited
    • e-Therapeutics Plc
    • Evec, Inc.
    • GangaGen Inc.
    • ImmunoBiology Limited
    • Immuron Limited
    • Inovio Pharmaceuticals, Inc.
    • Integrated BioTherapeutics, Inc.
    • MedImmune, LLC
    • Merck & Co., Inc.
    • MGB Biopharma Limited
    • Microbiotix, Inc.
    • Micropharm Limited
    • Morphochem AG
    • Nanotherapeutics, Inc.
    • Novabiotics Limited
    • NovoBiotic Pharmaceuticals, LLC
    • Oragenics, Inc.
    • Otsuka Holdings Co., Ltd.
    • Pfizer Inc.
    • Procarta Biosystems Limited
    • Prokarium Limited
    • Rebiotix Inc.
    • Sanofi Pasteur SA
    • Seres Therapeutics, Inc.
    • Shire Plc
    • Sorrento Therapeutics, Inc.
    • Stellar Biotechnologies, Inc.
    • Summit Therapeutics Plc
    • Synthetic Biologics, Inc.
    • Valevia UK Limited
    • Valneva SE
    • VaxInnate Corporation
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (actoxumab + bezlotoxumab) - Drug Profile
    • (miconazole nitrate + nisin) - Drug Profile
    • ABCD-01 - Drug Profile
    • ABM-101 - Drug Profile
    • actoxumab - Drug Profile
    • Antibodies for Enterocolitis - Drug Profile
    • Antibodies to Inhibit CD Toxin A and Toxin B for Clostridium difficile Infections - Drug Profile
    • AP-114 - Drug Profile
    • ATI-1501 - Drug Profile
    • ATx-401 - Drug Profile
    • AvR2-V10 - Drug Profile
    • bezlotoxumab - Drug Profile
    • Biologic for Clostridium difficile Infection - Drug Profile
    • Biologic for Clostridium difficile Infections - Drug Profile
    • C-3CD17 - Drug Profile
    • cadazolid - Drug Profile
    • Cdiff snare - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • CRS-3123 - Drug Profile
    • DAV-132 - Drug Profile
    • Drugs for Clostridium difficile Infection - Drug Profile
    • DS-2969 - Drug Profile
    • EV-029104 - Drug Profile
    • EV-029105A - Drug Profile
    • fidaxomicin - Drug Profile
    • IMM-529 - Drug Profile
    • INS-001 - Drug Profile
    • INS-5010 - Drug Profile
    • INX-201 - Drug Profile
    • MBX-500 - Drug Profile
    • MCB-3681 - Drug Profile
    • MGBBP-3 - Drug Profile
    • Monoclonal Antibodies for Clostridium difficile - Drug Profile
    • Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections - Drug Profile
    • Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile
    • Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
    • NP-432 - Drug Profile
    • OG-253 - Drug Profile
    • OPS-2071 - Drug Profile
    • OraCAb - Drug Profile
    • P-100031 - Drug Profile
    • P-4A - Drug Profile
    • PF-06425090 - Drug Profile
    • PolyCAb - Drug Profile
    • PRO-391 - Drug Profile
    • ramoplanin - Drug Profile
    • RBX-2660 - Drug Profile
    • RBX-7455 - Drug Profile
    • ridinilazole - Drug Profile
    • SER-109 - Drug Profile
    • SER-262 - Drug Profile
    • Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile
    • Small Molecules for Clostridium Difficile Infections - Drug Profile
    • Small Molecules for Clostridium Difficile Infections - Drug Profile
    • Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
    • Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile
    • Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile
    • SQ-641 - Drug Profile
    • SYN-004 - Drug Profile
    • SYN-006 - Drug Profile
    • VAL-301 - Drug Profile
    • VLA-84 - Drug Profile
    • VP-20621 - Drug Profile
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Recent Pipeline Updates
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2016
  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Limited, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Adenium Biotech ApS, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics B.V., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corporation, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Angothera GmbH, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3 Jian, Inc, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by e-Therapeutics Plc, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Limited, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Limited, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MedImmune, LLC, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co., Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Limited, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Limited, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Morphochem AG, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Limited, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Procarta Biosystems Limited, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Limited, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Shire Plc, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Stellar Biotechnologies, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics, Inc., H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Limited, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by VaxInnate Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics - Recent Pipeline Updates, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects (Contd..1), H1 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2016
  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top